Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics.
Kam Lun Ellis HonJoyce Tik Sze LiAlexander K C LeungVivian Wing Yan LeePublished in: Expert opinion on pharmacotherapy (2021)
Second-generation H1-antihistamines remain the first-line therapeutic options for the management of CSU. For patients not responding to higher-dose H1-antihistamines, international guidelines recommend the addition of omalizumab. Efficacy and safety data for newer agents are still pending. Large-scale, well-designed, randomized, double-blind, placebo-controlled trials will further provide evidence on the safety profile and efficacy of these agents in patients with CSU.
Keyphrases
- placebo controlled
- double blind
- phase iii
- clinical trial
- end stage renal disease
- phase ii
- newly diagnosed
- chronic kidney disease
- open label
- phase ii study
- small molecule
- patient reported outcomes
- squamous cell carcinoma
- randomized controlled trial
- smoking cessation
- electronic health record
- clinical practice
- machine learning
- big data